SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS) had its price target cut by HC Wainwright from $9.00 to $7.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently weighed in on SABS. Guggenheim started coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price target on the stock. UBS Group started coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Chardan Capital reissued a “buy” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

SAB Biotherapeutics Trading Up 6.8%

NASDAQ SABS opened at $4.10 on Tuesday. The stock has a market cap of $195.20 million, a P/E ratio of -1.77 and a beta of 0.59. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The stock has a 50 day simple moving average of $3.98 and a two-hundred day simple moving average of $3.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SABS. Vivo Capital LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth about $22,954,000. Commodore Capital LP purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $8,847,000. RA Capital Management L.P. purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $8,847,000. Woodline Partners LP bought a new stake in SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP bought a new stake in SAB Biotherapeutics during the fourth quarter worth about $8,222,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.